News und Analysen
Verimatrix To Highlight Latest Mobile App Security Innovations at droidcon San Francisco and Berlin
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced it’s scheduled to exhibit
FOCUS ENTERTAINMENT: PulluP Entertainment successfully completes its capital increase with a priority period and total gross amount of €23.08m after full exercise of the extension clause and th
Freelance.com: 1 st quarter 2024 revenue: €258.2m (+24%)
Kaufman & Broad SA: VOTING RESULTS OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF 6 MAY 2024
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Vochlea Music entscheidet sich für Verimatrix XTD
Verimatrix, (Euronext Paris: VMX), der führende Anbieter von Sicherheit für die moderne vernetzte Welt, gab heute bekannt, dass sich das britische Unternehmen Vochlea Music für Verimatrix XTD
FOCUS ENTERTAINMENT: PulluP Entertainment is launching a capital increase by way of a public offering with a priority period, on an irreducible basis only, for the benefit of shareholders, for an init
Vochlea Music Selects Verimatrix XTD
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that UK-based Vochlea Music chose Verimatrix
Verimatrix XTD Enterprise Suite triumphiert bei 2024 Cybersecurity Excellence Awards
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), ein führender Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, teilte heute mit, dass seine Verimatrix XTD
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Verimatrix XTD Enterprise Suite Triumphs at 2024 Cybersecurity Excellence Awards
Regulatory News:
Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD
Kaufman & Broad SA: ORDINARY AND EXTRAORDINARY SHAREHOLDERS’MEETING 2024, MAY 6
Kaufman & Broad SA: DIVIDEND PAYMENT IN RESPECT OF THE FINANCIAL YEAR ENDED NOVEMBER 30, 2023
Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM 2024
Die ESI Group stellt gemeinsam mit Aberdeen Strategy and Research „Shift-Left-Erkenntnisse“ über das virtuelle Prototyping bereit
Aufsichtsrechtliche Meldungen:
Die ESI Group (Paris: ESI) kooperiert mit den Branchenanalysten von Aberdeen Strategy and Research, um neue Erkenntnisse über die Vorteile des virtuelle
ESI Group Collaborates with Aberdeen Strategy and Research to Unveil "Shift Left" Insights on Virtual Prototyping
Regulatory News:
ESI Group (Paris:ESI) has partnered with industry analysts Aberdeen Strategy and Research to present novel insights into the benefits of virtual prototyping for digital
RTL Luxemburg setzt Verimatrix Streamkeeper ein, um seine wertvollen Motorsportinhalte vor Piraterie zu schützen
Verimatrix, (Euronext Paris: VMX), der führende Anbieter von Sicherheitslösungen für die moderne vernetzte Welt, gab heute bekannt, dass RTL Luxembourg, das führende Medienunternehmen des Landes
RTL Luxembourg Deploys Verimatrix Streamkeeper to Protect Premier Auto Racing from Piracy
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that RTL Luxembourg, the country’s leading
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic